the development of anti-fibrotic agents for treating myelofibrosis
Published 2 months ago • 165 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
2:13
exciting agents and treatment approaches emerging in the field of myelofibrosis
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
45:36
panel discussion | marketing 2.0 conference
-
6:44
how does jakafi® (ruxolitinib) work?
-
2:44
myelofibrosis: jenson shares his experience
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
4:20
therapy-related all: etiology, prognosis, and treatment
-
1:58
current barriers to early intervention in myelofibrosis
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis